Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress

Rhea-AI Summary

Liquidia (NASDAQ: LQDA) will present three clinical posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress in Dublin, Ireland, Jan 28–Feb 1, 2026.

The presentations cover interim and open-label clinical data for inhaled treprostinil products: LIQ861 (YUTREPIA) in PH-ILD from the ASCENT study to Week 24, and 48-week open-label data for investigational L606 in PAH and PH-ILD. Specific sessions: Paper 83 on Jan 29 (3:45–5:00 p.m. GMT), Paper 166 on Jan 30 (3:10–4:15 p.m. GMT), and Paper 82 on Jan 31 (9:55–11:00 a.m. GMT). Posters will be posted on Liquidia’s publications webpage after the conference.

Key Figures

Number of posters: 3 posters Congress dates: January 28–February 1, 2026 ASCENT interim duration: Week 24 +5 more

8 metrics

Number of posters 3 posters PVRI 2026 Annual Congress presentations

Congress dates January 28–February 1, 2026 PVRI 2026 Annual Congress in Dublin

ASCENT interim duration Week 24 ASCENT open-label study in PH-ILD with LIQ861

L606 data duration 48-week Open-label data for L606 in PAH and PH-ILD

Paper number LIQ861 83 ASCENT LIQ861 PH-ILD poster at PVRI 2026

Paper number L606 166 L606 open-label PAH/PH-ILD poster at PVRI 2026

Paper number ASCENT effort 82 Cardiac effort changes in ASCENT PH-ILD poster

Presentation times 3:45–5:00 p.m., 3:10–4:15 p.m., 9:55–11:00 a.m. GMT Scheduled PVRI poster sessions

Market Reality Check

Price: $42.48 Vol: Volume 1,383,383 shares i...

low vol

$42.48 Last Close

Volume Volume 1,383,383 shares is below the 20-day average of 2,159,252, suggesting no unusual trading ahead of the PVRI data presentations. low

Technical Shares at $42.21 are trading above the 200-day MA of $23.18 and sit within 1.19% of the 52-week high of $42.72.

Peers on Argus

LQDA is up 3.99% while only one peer in the momentum scanner, IBRX, shows activi...

1 Down

LQDA is up 3.99% while only one peer in the momentum scanner, IBRX, shows activity and is moving down 4.04%, pointing to a stock-specific move rather than a sector-wide rotation.

Historical Context

5 past events · Latest: Jan 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 09	Sales update	Positive	+12.9%	Preliminary 2025 YUTREPIA net sales and cash position update.
Jan 07	Conference appearance	Positive	+0.9%	Announcement of CEO presentation at J.P. Morgan Healthcare Conference.
Nov 03	Investor conferences	Positive	+3.5%	Upcoming UBS and Jefferies healthcare conference presentations.
Nov 03	Earnings report	Positive	+3.5%	Q3 2025 financial results showing YUTREPIA launch momentum.
Oct 27	Earnings pre-announcement	Neutral	+1.7%	Scheduling of Q3 2025 results release and webcast details.

Pattern Detected

Recent news, especially around YUTREPIA commercial metrics and financial updates, has generally been followed by positive share price reactions.

Recent Company History

Over the last few months, Liquidia has highlighted strong commercial traction for YUTREPIA, with preliminary 2025 net product sales of $148.3M and positive cash flow in Q4 2025. Earnings for Q3 2025 showed product sales of $51.7M and improving profitability. Multiple conference and investor presentations on Nov 3, 2025 and at J.P. Morgan in Jan 2026 also coincided with modest gains. Today’s PVRI clinical data presentations extend this pattern of showcasing the YUTREPIA and L606 portfolio alongside prior commercial momentum.

Market Pulse Summary

This announcement highlights Liquidia’s plan to present three posters at the PVRI 2026 Congress, sho...

Analysis

This announcement highlights Liquidia’s plan to present three posters at the PVRI 2026 Congress, showcasing 24-week ASCENT data for LIQ861 in PH-ILD, 48-week open-label data for L606 in PAH and PH-ILD, and cardiac effort analyses from ASCENT. These updates build on prior milestones in YUTREPIA commercialization and L606 development. Investors may watch for safety, tolerability and exploratory efficacy signals, as well as how these data support future study designs and broader portfolio positioning.

Key Terms

pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, treprostinil, open-label, +2 more

6 terms

pulmonary arterial hypertension medical

"clinical data in pulmonary arterial hypertension (PAH) and pulmonary hypertension"

Pulmonary arterial hypertension is a progressive medical condition in which the arteries that carry blood from the heart to the lungs become narrowed or stiff, causing high pressure in the lung circulation and extra strain on the heart — like a pump working against clogged pipes. For investors, it matters because the condition defines the need, market size, clinical trial design, regulatory hurdles and potential revenue or risk for companies developing drugs, devices or diagnostics to treat or manage it.

pulmonary hypertension associated with interstitial lung disease medical

"pulmonary hypertension associated with interstitial lung disease (PH-ILD) with LIQ861"

High blood pressure in the vessels of the lungs that develops because the lung tissue has become scarred or inflamed; think of the heart trying to push blood through lungs whose tiny pipes have narrowed or stiffened. It matters to investors because this combined condition creates a clear medical need that can drive demand for new drugs, devices and tests, influence the outcome of clinical trials and regulatory decisions, and affect costs and revenues across healthcare companies.

treprostinil medical

"YUTREPIA™ (treprostinil) inhalation powder, and L606, an investigational"

Treprostinil is a prescription drug that widens and relaxes the small blood vessels in the lungs to lower high blood pressure there and help people breathe and move more easily; it comes in several forms such as injection, infusion, inhalation or tablets. For investors it matters because approval status, patent protection, manufacturing complexity, competition from other treatments, and ongoing clinical trials directly affect a company’s sales potential, regulatory risk, and long-term revenue—think of it as a product line whose market success depends on safety, access, and differentiation.

open-label medical

"additional interim data from the open-label ASCENT study evaluating LIQ861"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

liposomal medical

"Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects"

Liposomal describes a formulation that uses tiny, bubble-like spheres made from fats (lipid bilayers) to carry and protect an active drug or compound. For investors, liposomal versions can change how a medicine is absorbed, how long it lasts in the body, and its side‑effect profile — like sending a fragile package in padded mail — which affects clinical success, regulatory review, manufacturing complexity, and potential market value.

interstitial lung disease medical

"pulmonary hypertension associated with interstitial lung disease (PH-ILD)"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

AI-generated analysis. Not financial advice.

MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with LIQ861, approved in the United States as YUTREPIA™ (treprostinil) inhalation powder, and L606, an investigational extended-release formulation of inhaled treprostinil.

Dr. Rajeev Saggar, Liquidia’s Chief Medical Officer, said: “We are pleased to present additional interim data from the open-label ASCENT study evaluating LIQ861in PH-ILD, as well as the 48-week open-label data for L606 in PAH and PH-ILD at PVRI. We are excited for the opportunity to showcase the strength and breadth of our data, and the potential impact it may have for patients and the global medical community.”

Title: Safety and Exploratory Efficacy data of LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD patients: ASCENT to Week 24
Date and time: Thursday, January 29, 2026, 3:45 – 5:00 p.m. GMT
Paper Number: 83
Presenting Author: Seth Hall, MBA, RRT, RRT-ACCS, RRT-NPS, Liquidia

Title: Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects with Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Date and time: Friday, January 30, 2026, 3:10 - 4:15 p.m. GMT
Paper Number: 166
Presenting Author: Dr. Rajeev Saggar, Liquidia

Title: Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from the ASCENT Trial
Date and time: Saturday, January 31, 2026, 9:55 – 11:00 a.m. GMT
Paper Number: 82
Presenting Author: Dr. James White, University of Rochester Medical Center

Following the presentations, the posters will be available on Liquidia’s website at https://liquidia.com/publications.

About ASCENT
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH (ASCENT), listed as ClinicalTrials.gov ID NCT06129240, will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 and 3 pulmonary hypertension. Cohort A includes 54 subjects who have WHO Group 3 Pulmonary Hypertension associated with interstitial lung disease (PH-ILD). Additional cohorts from either Group 1 or Group 3 may be defined in future protocol amendments. Scheduled study visits to the clinic will occur at Screening, Baseline, Week 8, Week 16, Week 24, and Week 52. During this time, dose titration may be ordered at the Investigator's discretion and in accordance with the guidance provided. The primary objective of this study is to evaluate the safety and tolerability of LIQ861 in subjects with WHO Group 1 & 3 Pulmonary Hypertension (PH). The exploratory objectives of the study are to assess the effects of LIQ861 on exercise capacity, functional class, relevant biomarkers, and imaging assessments.

About YUTREPIA™ (treprostinil) Inhalation Powder
YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT® Technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.

About L606 (treprostinil liposome inhalation suspension)
L606 is an investigational, extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer. The L606 suspension uses a proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) and a global pivotal placebo-controlled efficacy study for the treatment of PH-ILD.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
Jason.adair@liquidia.com

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com

FAQ

What clinical data will Liquidia (LQDA) present at PVRI 2026?

Liquidia will present interim ASCENT Week 24 data for LIQ861 (YUTREPIA) in PH-ILD and 48-week open-label data for investigational L606 in PAH and PH-ILD.

When and where will Liquidia (LQDA) present at the PVRI 2026 Annual Congress?

PVRI 2026 runs Jan 28–Feb 1 in Dublin, Ireland; Liquidia presentations are Jan 29 (3:45–5:00 p.m. GMT), Jan 30 (3:10–4:15 p.m. GMT) and Jan 31 (9:55–11:00 a.m. GMT).

Which Liquidia poster covers safety and exploratory efficacy of LIQ861 in PH-ILD?

Paper Number 83 titled Safety and Exploratory Efficacy data of LIQ861 in PH-ILD (ASCENT to Week 24) will be presented on Jan 29, Paper 83.

Who are the presenting authors for Liquidia’s PVRI posters?

Presenters listed are Seth Hall (Paper 83), Dr. Rajeev Saggar (Paper 166), and Dr. James White (Paper 82).

Will Liquidia post the PVRI posters online and where can investors find them?

Yes, the posters will be available on Liquidia’s publications webpage at https://liquidia.com/publications following the presentations.